Angiotensin II Suppression in Humans by the Orally Active Renin Inhibitor Aliskiren (SPP100)
Top Cited Papers
- 1 January 2002
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Hypertension
- Vol. 39 (1) , E1-8
- https://doi.org/10.1161/hy0102.102293
Abstract
Renin is the main determinant of angiotensin (Ang) II levels. It, therefore, always appeared desirable to reduce Ang II levels by direct inhibition of renin. So far, specific renin inhibitors lacke...Keywords
This publication has 25 references indexed in Scilit:
- Efficacy and tolerability of losartan versus enalapril alone or in combination with hydrochlorothiazide in patients with essential hypertensionClinical Therapeutics, 1995
- Determinants of angiotensin II generation during converting enzyme inhibition.Hypertension, 1990
- Effects of renin inhibition in the conscious primate Macaca fascicularis.Hypertension, 1989
- Hemodynamic and biochemical consequences of renin inhibition by infusion of CGP 38560A in normal volunteers.Hypertension, 1989
- Hemodynamic and humoral effects of the new renin inhibitor enalkiren in normal humans.Hypertension, 1989
- A highly potent and long-acting oral inhibitor of human renin.Hypertension, 1988
- An orally active inhibitor of renin.Hypertension, 1986
- EnalaprilDrugs, 1986
- True versus immunoreactive angiotensin II in human plasma.Hypertension, 1985
- CAPTOPRIL IN THE TREATMENT OF CLINICAL HYPERTENSION AND CARDIAC FAILUREThe Lancet, 1979